Alkermes stock maintains Buy rating at Stifel after narcolepsy drug results
NeutralFinancial Markets

Alkermes has maintained a 'Buy' rating from Stifel following positive results from its narcolepsy drug. This endorsement is significant as it reflects confidence in the company's product and its potential impact on the market for narcolepsy treatments. The stock rating suggests that analysts believe Alkermes is a worthwhile investment, which could influence investor sentiment and market performance.
— via World Pulse Now AI Editorial System
